Clinical trial NCT01050439: Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Official title: Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Leukemia
Lymphoma
Bone Marrow Failure Syndromes
Immunodeficiencies
Histiocytosis
Keywords: Allogeneic Stem Cell Transplant
Unrelated donor
Cord blood donor
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2010-01-15
Enrollment: 22
Sex: ALL
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree of engraftment in patients with selected malignant and non malignant disorders.

Detailed description: This is a non-randomized study to determine the tolerability and degree of engraftment of unrelated matched donor allogeneic stem cell transplantation with either myeloablative or reduced intensity conditioning in patients with selected malignant and non malignant disorders. Patients will receive one of either full intensity or reduced intensity regimen based on the patient's disease status, organ function and performance and determined by the PI.

Eligibility criteria: Inclusion Criteria:

* Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or \> 40 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range.
* Adequate liver function defined as: total bilirubin \< 2.5 x normal; or SGOT (AST) or SGPT (ALT) \< 5.0 x normal.
* Adequate cardiac function defined as: shortening fraction of \> 25% by echocardiogram, or ejection fraction of \> 40% by radionuclide angiogram or echocardiogram.
* Adequate pulmonary function defined as: DLCO \> 35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% in room air.
* Diseases:

  * CML (CP, AP or BC)
  * AML/MDS/JCML
  * ALL
  * Lymphoma (Hodgkin's and non-Hodgkin's)
  * Non-malignant disorders
* Bone Marrow Failure Syndromes: Patients with the following diagnoses are eligible:

  * Severe Aplastic Anemia:
  * Fanconi Anemia
  * Severe Congenital Neutropenia (Kostmann's Syndrome)
  * Amegakaryocytic Thrombocytopenia
  * Diamond-Blackfan Anemia
  * Infantile Osteopetrosis
  * Schwachman-Diamond Syndrome
  * Dyskeratosis Congenita
  * Other bone marrow failure syndromes at discretion of Principal Investigator
* Immunodeficiencies:

  * SCIDS, all subtypes
  * Combined Immunodeficiency Syndrome
  * Wiskott-Aldrich syndrome
  * Chronic Granulomatous Disease
  * Chediak-Higashi Syndrome
  * Leukocyte Adhesion Deficiency
  * Other immunodeficiencies at discretion of Principal Investigator
* Inborn Errors of Metabolism (IEOM):

  * Transplant is recommended for the following disorders: Hurler syndrome (L-iduronidase deficiency, MPS-I), Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency, MP VI), Sly syndrome (glucuronidase deficiency, MPS-VII), Globoid cell Leukodystrophy (galactocerebrosidasedeficiency), Metachromatic leukodystrophy (arylsulfatase A deficiency), Childhood-onset X-linked adrenoleukodystrophy (X-ALD), Fucosidosis (fucosidase deficiency), Mannosidosis, Aspartylglucosaminuria, Niemann-Pick Disease Type B (acid sphingomyelinase deficiency), Gaucher disease (glucocerebrosidase deficiency) Type I (non neuropathic), Other diagnoses may be considered at the discretion of the Principal Investigator
  * For X-ALD patients greater than 5 years of age, IQ \> 80 is required. For other patients greater than 5 years of age, IQ \> 70 is required.
  * For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation.
* Histiocytosis:

  * Hemophagocytic Lymphohistiocytosis (HLH)
  * Familial Erythrophagocytic Lymphohistiocytosis
  * Langerhans Cell Histiocytosis
  * Malignant Histiocytosis
* Other Malignant and non-malignant diseases: Other malignant and non-malignant diseases not listed above may be eligible if deemed appropriate by the Principal Investigator.

Exclusion Criteria:

* Women who are pregnant and/or breast feeding are ineligible

Primary outcomes:
measure: Incidence of toxicity related to myeloablative therapy
timeFrame: Up to 10 years from start of study
Secondary outcomes:
measure: Incidence of toxicity related to reduced intensity therapy
timeFrame: Up to 10 years from start of study
measure: Percentage of donor chimerism
timeFrame: Up to 10 years from start of study
measure: Prevalence of progression free survival
timeFrame: Up to 10 years from start of study
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Mitchell S Cairo, MD
role: PRINCIPAL_INVESTIGATOR
References: